公开(公告)号：US12090174B2

公开(公告)日：2024-09-17

申请号：US16887971

申请日：2020-05-29

申请人： SPINALCYTE, LLC

发明人： Pete O'Heeron ,  Thomas Ichim

IPC分类号： A61K35/33 ,  A61K9/00 ,  A61K35/17 ,  C12N5/077

CPC分类号： A61K35/33 ,  A61K35/17 ,  C12N5/0656 ,  A61K9/0019 ,  C12N2502/1114

摘要： Disclosed are compositions and methods of treating muscular dystrophies, including Duchenne Muscular Dystrophy (DMD) through administration of fibroblasts and modified fibroblasts systemically and locally. In certain embodiments, fibroblast cells are utilized for replacement of dystrophin through fusion and/or other means of horizontal gene transfer. In other embodiments, the disclosure teaches the use of fibroblasts for reduction of inflammatory reactions and/or immunological reactions which propagate and enhance myodestructive aspects of Duchenne Muscular Dystrophy. In other embodiments, fibroblasts are utilized as vectors for gene therapy and/or gene modifications approaches.

公开(公告)号：US20240269188A1

公开(公告)日：2024-08-15

申请号：US18390569

申请日：2023-12-20

申请人： Rutgers, The State University of New Jersey

发明人： Yufang Shi ,  Guangwen Ren ,  Liying Zhang

IPC分类号： A61K35/28 ,  A61K35/12 ,  A61K38/18 ,  A61K38/19 ,  A61K38/20 ,  A61K38/21 ,  A61K45/06 ,  A61P37/02 ,  A61P37/04 ,  A61P37/06 ,  C07K14/495 ,  C07K14/50 ,  C07K14/52 ,  C07K14/525 ,  C07K14/545 ,  C07K14/56 ,  C07K14/565 ,  C07K14/57 ,  C12N5/00 ,  C12N5/074 ,  C12N5/0775

CPC分类号： A61K35/28 ,  A61K38/1825 ,  A61K38/1841 ,  A61K38/191 ,  A61K38/20 ,  A61K38/2006 ,  A61K38/212 ,  A61K38/215 ,  A61K38/217 ,  A61P37/04 ,  A61P37/06 ,  C12N5/0018 ,  C12N5/0607 ,  C12N5/0662 ,  C12N5/0663 ,  C12N5/0665 ,  A61K2035/122 ,  A61K45/06 ,  A61P37/02 ,  C07K14/495 ,  C07K14/50 ,  C07K14/52 ,  C07K14/525 ,  C07K14/545 ,  C07K14/56 ,  C07K14/565 ,  C07K14/57 ,  C12N2500/05 ,  C12N2501/10 ,  C12N2501/115 ,  C12N2501/15 ,  C12N2501/2301 ,  C12N2501/2317 ,  C12N2501/24 ,  C12N2501/25 ,  C12N2502/1114

摘要： The present invention provides methods or kits with inflammatory cytokines to pretreat 1-ISCs to augment their immune modulatory effect, in prevention and treatment of various diseases such as multiple sclerosis, arthritis, lupus, sepsis, hepatitis, cirrhosis, Parkinson's disease, chronic infections, and GvHD. The present invention relates to novel methods for enhancing the immunosuppressive or the immune stimulatory activities of mesenchymal stem cells (JvfSCs).

公开(公告)号：US11969463B2

公开(公告)日：2024-04-30

申请号：US16637927

申请日：2018-08-10

申请人： GOOD T CELLS, INC.

发明人： Jung Ho Kim ,  Beom Seok Kim

IPC分类号： C07K14/435 ,  A61K35/17 ,  A61K38/16 ,  A61K38/17 ,  A61K39/00 ,  C12N5/0783 ,  C12N15/869

CPC分类号： A61K39/0011 ,  A61K35/17 ,  A61K38/162 ,  A61K38/1774 ,  C12N5/0636 ,  C12N15/869 ,  C12N2501/22 ,  C12N2501/2302 ,  C12N2501/2304 ,  C12N2501/2307 ,  C12N2501/2312 ,  C12N2501/2315 ,  C12N2501/2321 ,  C12N2501/24 ,  C12N2501/25 ,  C12N2502/1107 ,  C12N2502/1114 ,  C12N2502/1121 ,  C12N2502/1157

摘要： The present invention relates to a cancer-specific tumor antigen neoepitope represented by any one of SEQ ID NOs: 1 to 214, an antigen-presenting cell loaded with the neoepitope, and a method for activating T cells for cancer treatment using the antigen-presenting cell. An antigen-presenting cell, that is, a dendritic cell, loaded with a cancer-specific tumor antigen epitope provided in the present invention enables rapid and effective induction of differentiation and proliferation of cancer antigen-specific T cells, preferably memory T cells, and the memory T cells thus activated can treat a cancerous or neoplastic condition or prevent recurrence, progression, or metastasis of cancer while avoiding the defense mechanism of cancer cells.

公开(公告)号：US20240082375A1

公开(公告)日：2024-03-14

申请号：US18477810

申请日：2023-09-29

申请人： Iovance Biotherapeutics, Inc.

发明人： Michelle R. Simpson-Abelson ,  Matthew J. Frigault ,  Wayne P. Rothbaum ,  Michael Weiser

IPC分类号： A61K39/00 ,  C12N5/0783 ,  G01N33/50 ,  G01N33/68

CPC分类号： A61K39/0011 ,  C12N5/0638 ,  G01N33/5008 ,  G01N33/505 ,  G01N33/6866 ,  A61K2039/5158 ,  A61K2039/545 ,  A61K2039/55533 ,  C12N2501/2302 ,  C12N2502/1114 ,  C12N2502/30 ,  C12N2503/00 ,  G01N2333/57 ,  G01N2500/10

摘要： The present invention provides novel processes, compositions, and methods for analyzing or assaying the potency and/or functionality of tumor infiltrating lymphocyte (TIL) products for use in therapy, including human cancer therapy, and analyzing or assaying the potency and/or functionality of other polyclonal products, such as marrow infiltrating lymphocyte (MIL) and peripheral blood lymphocyte (PBL) products. Compositions, methods, and kits for preparing and treating cancer using TIL, MIL, and PBL products are also provided.

公开(公告)号：US20240076617A1

公开(公告)日：2024-03-07

申请号：US18506851

申请日：2023-11-10

申请人： Juno Therapeutics, Inc.

发明人： Mirna MUJACIC ,  Ayu RAHARDJO

IPC分类号： C12N5/0783 ,  A61K35/17 ,  C12N7/00 ,  C12N15/86 ,  G01N33/569

CPC分类号： C12N5/0636 ,  A61K35/17 ,  C12N7/00 ,  C12N15/86 ,  G01N33/56972 ,  C12N2502/1114 ,  C12N2740/13043 ,  C12N2740/15043 ,  G01N2333/70514 ,  G01N2333/70517

摘要： Provided herein are methods and compositions for generating engineered cells, such as cells expressing a recombinant receptor, including methods involving stimulation and/or engineering of an input composition having a defined ratio of naïve-like CD4+ T cells to naïve-like CD8+ T cells. In particular, the methods can be used to engineer T cells with genetically engineered receptors, such as genetically engineered antigen receptors such as engineered (recombinant) TCRs and chimeric antigen receptors (CARs), or other recombinant chimeric receptors. Features of the methods include producing a more consistent and/or predictable T cell product and/or a product with lower toxicity compared with other methods.

公开(公告)号：US20230310608A1

公开(公告)日：2023-10-05

申请号：US18003279

申请日：2021-07-01

申请人： TCER ONCOLOGY AB

发明人： Hans GRÖNLUND ,  Rolf KIESSLING ,  Stina WICKSTRÖM

IPC分类号： A61K39/00 ,  A61P35/00 ,  C12N5/0784 ,  C12N5/0783

CPC分类号： A61K39/46449 ,  A61K39/4611 ,  A61K39/00119 ,  A61P35/00 ,  C12N5/0639 ,  C12N5/0638 ,  A61K2039/5154 ,  A61K2039/5158 ,  C12N2502/1121 ,  C12N2502/1114

摘要： The present invention provides an in vitro method for the manufacture of a dendritic cell (DC) cancer vaccine, said method comprising the steps of: (i) providing a plurality of phagocytosable particles, wherein each phagocytosable particle comprises a core and an antigenic construct tightly associated to the core, wherein the antigenic construct comprises at least one epitope peptide having an amino acid sequence corresponding to an amino acid sequence of a part of a protein or peptide known or suspected to be expressed by a cancer cell in a subject; (ii) providing a sample of DCs; and (iii) contacting the sample of DCs with the plurality of phagocytosable particles in vitro and under conditions allowing for the phagocytosis of at least one phagocytosable particle by a DC. The present invention also provides a DC cancer vaccine produced by the method of the invention, and the use a DC cancer vaccine of the invention as a medicament and for the ex vivo expansion of anticancer T-cells.

公开(公告)号：US20180256646A1

公开(公告)日：2018-09-13

申请号：US15974307

申请日：2018-05-08

申请人： CASE WESTERN RESERVE UNIVERSITY

发明人： M. Edward Medof ,  Jinbo Liu ,  Michael G. Strainic

IPC分类号： A61K35/17 ,  C12N5/0783 ,  A61K38/00 ,  A61K35/12

CPC分类号： A61K35/17 ,  A61K38/00 ,  A61K39/3955 ,  A61K2035/122 ,  A61K2035/124 ,  A61K2039/505 ,  C07K16/2875 ,  C07K2317/76 ,  C12N5/0636 ,  C12N5/0639 ,  C12N2501/998 ,  C12N2502/1114 ,  C12N2502/1178 ,  Y02A50/401 ,  Y02A50/414 ,  A61K2300/00

摘要： A method of method of inhibiting Toll like receptor (TLR) signaling in dendritic cells (DCs) of a subject in need thereof includes administering at least one complement antagonist to the DCs at an amount effective to substantially inhibits C3a receptor (C3aR) and/or C5a receptor (C5aR) signal transduction in the DCs induced by TLR signaling.

公开(公告)号：US20180208895A1

公开(公告)日：2018-07-26

申请号：US15516731

申请日：2015-10-05

申请人： Assistance Publique - Hopitaux de Paris ,  Fondation Imagine - Institut Des Maladies Genetiques ,  Universtie Paris Descartes ,  Institut National de la Sante et de la Recherche Medicale (INSERM)

发明人： Marina Cavazzana-Calvo ,  Isabelle Andre-Schmutz ,  Chantal Lagresle-Peyrou ,  Salima Hacein-Bey-Abina ,  Christian Reimann ,  Chantal De Chappedelaine

IPC分类号： C12N5/0783

CPC分类号： C12N5/0636 ,  C12N2501/42 ,  C12N2502/1114 ,  C12N2506/11 ,  C12N2533/50 ,  C12N2533/52

摘要： The invention relates to the field of cell therapy and to an in vitro method for generating T-cell progenitors, comprising the step of exposing CD34+ cells in a medium containing a Notch ligand, a soluble domain of the Delta-like ligand 4, joined to an Fc region of a protein IgG, in the presence of a fragment of fibronectin comprising the motifs RGDS and CS-1 and a heparin-binding domain.

公开(公告)号：US20170198010A1

公开(公告)日：2017-07-13

申请号：US15412760

申请日：2017-01-23

申请人： ONCOTHERAPY SCIENCE, INC.

发明人： Yusuke NAKAMURA ,  Takuya TSUNODA ,  Ryuji OSAWA ,  Sachiko YOSHIMURA ,  Tomohisa WATANABE ,  Gaku NAKAYAMA

IPC分类号： C07K7/06 ,  C12N5/0783 ,  A61K39/00

CPC分类号： C07K7/06 ,  A61K38/00 ,  A61K39/00 ,  A61K39/0011 ,  A61K2039/5154 ,  A61K2039/5158 ,  A61K2039/53 ,  C07K14/705 ,  C12N5/0638 ,  C12N2501/998 ,  C12N2502/1114 ,  C12N2502/1121 ,  G01N33/57407

摘要： The present invention provides isolated peptides or the fragments derived from SEQ ID NO: 42, which bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL). The peptides may include one of the above mentioned amino acid sequences with substitution, deletion, or addition of one, two, or several amino acids sequences. The present invention also provides pharmaceutical compositions including these peptides. The peptides of this invention can be used for treating cancer.

公开(公告)号：US20170114321A1

公开(公告)日：2017-04-27

申请号：US15354241

申请日：2016-11-17

申请人： LIFE TECHNOLOGIES CORPORATION

发明人： Ronald BERENSON ,  Mark BONYHADI ,  Dale KALAMASZ

IPC分类号： C12N5/00 ,  A61K35/17 ,  C12N5/0783

CPC分类号： C12N5/0087 ,  A61K35/17 ,  C12N5/0636 ,  C12N2501/48 ,  C12N2502/1114 ,  Y02A50/475

摘要： The present invention relates generally to methods for stimulating T cells, and more particularly, to methods to eliminate undesired (e.g., autoreactive, alloreactive, pathogenic) subpopulations of T cells from a mixed population of T cells, thereby restoring the normal immune repertoire of said T cells. The present invention also relates to compositions of cells, including stimulated T cells having restored immune repertoire and uses thereof.